A股申购 | 海圣医疗(920166.BJ)开启申购 产品应用于麻醉科、ICU病房、急诊科等科室的终端临床需求

Company Overview - Haiseng Medical (920166.BJ) has launched its subscription on February 4, with an issue price of 12.64 yuan per share and a subscription limit of 508,200 shares, reflecting a price-to-earnings ratio of 13.99 times. The company is listed on the Beijing Stock Exchange, with CITIC Securities as its sponsor [1] - Haiseng Medical is a global provider of anesthesia and monitoring medical devices, focusing on the research, production, and sales of these products, which are widely used in anesthesia departments, ICUs, and emergency departments [1] Product and Market Position - The company holds 53 domestic medical device registration certificates, including 11 Class III, 40 Class II, and 2 Class I certificates. Additionally, it has 2 FDA registrations and 12 products with EU CE certifications [1] - Haiseng Medical has established a sales network covering most provinces and cities in China, with its products used in over 1,000 tertiary hospitals and thousands of medical institutions, including more than 600 top-tier hospitals [4] Industry Growth - According to Frost & Sullivan, China's medical device market is growing rapidly, with the market size expected to increase from 440.3 billion yuan in 2017 to 1,154.4 billion yuan by 2024, representing a compound annual growth rate (CAGR) of 14.76%, significantly higher than the global CAGR of approximately 4.82% during the same period [4] - The domestic medical device market is anticipated to continue its growth, with projections indicating a market size of 1,244.2 billion yuan by 2025 and over 1.66 trillion yuan by 2030, driven by government support for domestic medical devices and increasing per capita medical spending [4] Financial Performance - The company reported revenues of approximately 268 million yuan, 306 million yuan, and 304 million yuan for the years 2022, 2023, and 2024, respectively, with net profits of approximately 70.11 million yuan, 78.04 million yuan, and 70.92 million yuan for the same years [7] - As of December 31, 2022, total assets were approximately 319.68 million yuan, with total equity of about 260.55 million yuan. By June 30, 2025, total assets are projected to reach approximately 519.45 million yuan, with total equity of about 446.96 million yuan [8] - The company has maintained a gross margin of around 51.59% to 53.15% over the past few years, with a net profit margin showing a slight fluctuation [8]